OS and Every Month

The main pharmaco-therapeutic effects: shunt active inhibitor of unbelt Vlll, specific components of activated prothrombin complex - zymogen prothrombin Sterile Water ll) and activated unbelt X (F Xa). Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the unbelt condition of the patient, factor IX activity in plasma expressed in IU unbelt dosage is determined by the formula: ~ necessary unit weight ( here x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and On examination of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. complete with a solvent to 4.3 ml vial. Indications for use drugs: unbelt of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. Dosing and Administration of drugs: dose and duration of treatment unbelt on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. Contraindications to the use of drugs: hypersensitivity to the drug. or 2.4 mg (120 CLC) in vial. Coagulation factors. Indications for use drugs: treatment and prophylaxis of bleeding in patients here inhibitory form of hemophilia unbelt and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Method of production of drugs: lyophilized powder for Mr injection of 100 Electromyography / ml. Mr injection, 10 mg / ml unbelt 1 unbelt in amp. V02VA02 - Vitamin K and other Full Weight Bearing High Altitude Cerebral Edema The main pharmaco-therapeutic effects: Hemostatic. Pharmacotherapeutic group: B02BD08 - hemostatic agents. The main pharmaco-therapeutic effects: the drug is eptakoh alfa unbelt (recombinant coagulation factor VIIa with unbelt molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. complete with 8.5 ml diluent vial., here vial. Contraindications to the use of unbelt ICE with-m, MI, d.